You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 8,436,190

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,436,190

Title:	Bendamustine pharmaceutical compositions
Abstract:	The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
Inventor(s):	Brittain; Jason Edward (El Cajon, CA), Franklin; Joe Craig (Tulsa, OK)
Assignee:	Cephalon, Inc. (Frazer, PA)
Application Number:	11/330,868
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,436,190
Patent Claims:	1. A pharmaceutical composition comprising bendamustine or bendamustine hydrochloride, mannitol, tertiary-butyl alcohol and water. 2. The pharmaceutical composition according to claim 1, wherein said bendamustine or bendamustine hydrochloride is present at a concentration of about 12 to 17 mg/ml, said mannitol is present at a concentration of about 20-30 mg/ml, and said tertiary-butyl alcohol is present at a concentration of about 10-50% (v/v). 3. The pharmaceutical composition according to claim 2, wherein said bendamustine or bendamustine hydrochloride is present at a concentration of about 15 mg/ml, said mannitol is present at a concentration of about 25.5. mg/ml, and said tertiary-butyl alcohol is present at a concentration of about 30% (v/v). 4. A lyophilized pharmaceutical composition made from the pharmaceutical composition according to claim 1. 5. The lyophilized pharmaceutical composition according to claim 4, wherein said bendamustine or bendamustine hydrochloride is present in said pharmaceutical composition at a concentration of about 12 to 17 mg/ml, said mannitol is present in said pharmaceutical composition at a concentration of about 20-30 mg/ml, and said tertiary-butyl alcohol is present in said pharmaceutical composition at a concentration of about 10-50% (v/v). 6. The lyophilized pharmaceutical composition according to claim 5, wherein said bendamustine or bendamustine hydrochloride is present in said pharmaceutical composition at a concentration of about 15 mg/ml, said mannitol is present in said pharmaceutical composition at a concentration of about 25.5 mg/ml, and said tertiary-butyl alcohol is present in said pharmaceutical composition at a concentration of about 30% (v/v). 7. The lyophilized pharmaceutical composition according to claim 4 containing not more than about 0.5% bendamustine ethylester. 8. The lyophilized pharmaceutical composition according to claim 5 containing not more than about 0.5% bendamustine ethylester. 9. The lyophilized pharmaceutical composition according to claim 6 containing not more than about 0.5% bendamustine ethylester.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.